Cargando…
Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
Traditional treatment failure in recurrent ovarian cancer remains a challenge for clinicians. Tumor genetic testing is a promising tool which has been proved able to identify sensitivity profiles in patients affected by cancers. This may be helpful in choosing targeted systemic treatments, aiming to...
Autores principales: | Cappuccio, Serena, Distefano, Maria Grazia, Ghizzoni, Viola, Fagotti, Anna, Scambia, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042411/ https://www.ncbi.nlm.nih.gov/pubmed/32128357 http://dx.doi.org/10.1016/j.gore.2020.100547 |
Ejemplares similares
-
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
por: Mendivil, Alberto A., et al.
Publicado: (2018) -
Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
por: Turco, Luigi Carlo, et al.
Publicado: (2020) -
One-Step Nucleic Acid Amplification (OSNA): A fast molecular test based on CK19 mRNA concentration for assessment of lymph-nodes metastases in early stage endometrial cancer
por: Fanfani, Francesco, et al.
Publicado: (2018) -
Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023) -
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
por: Ferrandina, Gabriella, et al.
Publicado: (2014)